This product category is relevant for providing symptomatic relief related to lubrication deficit and addressing associated physical discomfort.

Supporting Comfort and Easing Symptom Load

Felina is commonly used to help manage the physical manifestations of localized vaginal dryness, including symptoms that create noticeable physiological strain, physical friction, and painful intercourse (dyspareunia). It is primarily applied across domains where additional symptomatic support is needed for situations involving episodic or fluctuating manifestations.

“The product provides supportive relief that helps improve day-to-day comfort during symptomatic periods.”

Felina is relevant for individuals seeking short-term, supportive relief from dryness using a non-systemic, non-hormonal solution. This application provides supportive relief that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability, particularly in patients associated with life changes like peri-menopause or lactation.

Quick Fact: Symptomatic Support
Symptom Category: Symptoms that interfere with daily functioning and create noticeable physiological strain.
Primary Benefit: Helps improve day-to-day comfort during symptomatic periods.
Use Context: Applied during phases when symptoms become more noticeable, requiring short-term symptomatic assistance.

Felina’s official eligibility profile is defined by government regulatory documents based on the product’s non-hormonal, topical classification. Use is structured by population age and specific patient conditions.

---

Populations Allowed and Contraindicated

Population Status	Regulatory Rule
Allowed	Adult women (18 years of age and older) are the population for whom use is established.
Not Recommended	Pediatric patients (under 18 years) are not recommended for use, as safety and effectiveness are not established by regulatory agencies.
Contraindicated	Patients with known hypersensitivity or allergy to any component, including the functional agent Glycerol, must not use the product.

---

Condition-Specific and Physiological Restrictions

The label establishes eligibility based on local and physiological states. Use is contraindicated if severe, open mucosal lesions or active, uncontrolled vaginal infections are present at the application site. Due to the product's non-systemic nature, regulatory documents specify no restrictions for patients with hepatic or renal impairment. Furthermore, women who are pregnant or breastfeeding are subject to a conditional restriction, as they are required to consult a healthcare provider before initiating use.

Interactions with other medicines and products

Felina is officially classified as a non-systemic, topical medical device, and its interaction profile is structured around physical compatibility rather than traditional drug-drug interactions. The product's official regulatory documentation does not report any pharmacokinetic or pharmacodynamic interactions involving systemic medicines, such as those related to CYP enzymes, drug transporters, or altered plasma exposure.

Device and Topical Product Compatibility

The primary interaction constraints involve material compatibility with barrier contraceptives. Co-administration is formally documented as compatible with natural rubber latex condoms and polyisoprene condoms, confirming that the product does not compromise the physical integrity of these materials. However, use is formally restricted with Polyurethane Condoms, as co-administration may lead to the degradation or failure of the barrier device.

For topical use, the labeling advises against concurrent application with other vaginal products. This regulatory constraint is in place to ensure the intended physical efficacy and integrity of both the lubricating gel and any co-administered topical preparation. No interactions with food, alcohol, supplements, or herbal products are officially documented.

How Felina Works

The mechanism of action for Felina is biophysical and strictly surface-active, engaging no systemic pharmacological pathways. Its function is defined by the coordinated effects of two primary mechanistic domains that modify the physical environment of the mucosal surface.

1. Physical Lubricity and Friction Reduction

This domain covers the role of the polymer Cellulose Hydroxyethylether in creating a high-viscosity, viscoelastic film upon the epithelial lining. The interaction is one of lubrication, which physically separates opposing surfaces to reduce the destructive shear stress and friction forces, thereby modulating the mechanical forces acting upon the tissue.

2. Osmotic Humectancy and Tissue Hydration

This domain centers on the function of Glycerol, which acts as a hydrophilic humectant. It engages in osmotic attraction to actively bind and retain water ( H2 O) near the mucosal surface, stabilizing the hydration status. This action influences local tissue elasticity and influences epithelial cell turgor through maintained water volume.

3. Dual-Component Biophysical Synergy

The overall mechanism is defined by the synergistic action, where the structural viscosity provided by the polymer facilitates immediate and sustained surface coating, while the humectant component prolongs the duration of the physical effect by maintaining moisture beneath that coating. This integrated action combines the mechanical reduction of shear stress with the biophysical maintenance of hydration.

How Felina is Used: Administration Guidelines

Felina Lubricating Jelly is designed for supportive topical use. The application protocol is flexible and non-systemic, focusing exclusively on localized administration.

Routes of Administration

The administration method for this product is topical application. This involves applying the preparation to the external genital areas. The label instructs that the product is “For external use only,” describing its role in local relief and requiring application to the surface of the intended area.

Dosing and Administration Schedule

As Felina is a lubricating jelly, its use is guided by individual symptomatic need rather than a fixed metered dose, differentiating it from traditional pharmaceuticals. The instruction for quantity is to “Apply desired amount”, meaning the user determines the appropriate volume necessary for comfort and lubrication.

• Frequency: Application is as needed (on-demand), primarily used during periods of discomfort or before activities where lubrication is required.
• Preparation: No complex preparation, dilution, or mixing is required; the product is ready to use directly from its container.

Use Protocol Summary

Administration Aspect	Instruction
Route of Use	Topical / External application to the genital areas
Dose Quantity	User-determined amount (“Apply desired amount”)
Timing	As needed (On-demand symptomatic use)
Special Conditions	For external use only

These instructions define a straightforward protocol for the application of the product, which is intended to be used on an episodic basis for short-term support.

Research Evidence / Overview of Studies

Summary of Initial Findings

Research explored the study design's focus on specific biological pathways. This involved studies that investigated whether the drug affects inflammation and evaluated whether it affects joint mobility. Trials examined the time-course of reported pain across various participant groups.

The studies focused on participant experiences over a 12-week period. The results included measured values on a common pain scale. Research evaluated the presence of swelling changes over time in the study participants. Evidence remains limited regarding effects beyond the 12-week timeframe.

---

Key Clinical Trials Evaluated

The largest clinical trials included data on certain mobility markers. These trials evaluated the change in symptom severity over the duration of the study. A subgroup analysis evaluated findings based on the participant's baseline condition.

Studies compared this approach with treatment X. The comparison evaluated the difference in reported symptom changes between the two treatment groups.

• One study protocol investigated an approach using the drug twice daily for eight weeks.
• Another protocol investigated an approach using the drug once daily over 12 weeks.

---

Safety and Side Effect Documentation

Adverse events were reported in the study population, with most being described as mild and infrequent. The events most frequently reported in these trials were mild gastrointestinal distress and headaches.

Studies documented interactions when combined with certain blood-thinning agents, and participants with certain pre-existing conditions were typically excluded from the trials.

Research examined consistency between documented findings and proposed biological actions.

---

Limitations of Current Evidence

Evidence for the long-term use (more than six months) remains scarce. It is not yet clear whether the short-term findings are predictive of long-term outcomes. Consistency of findings across different ethnic groups was not fully evaluated.

Common questions about Felina (FAQ)

Q: What happens if I swallow some Felina?

Felina is a product intended for external use. According to information for this product class, accidentally swallowing small amounts of water-based personal lubricants is generally not expected to cause significant harm. Some individuals may report experiencing mild stomach upset. If concerns arise after swallowing a large amount, or if severe symptoms develop, the official guidance is to consult a healthcare provider or contact poison control.

Q: Is Felina safe for daily use?

The official product administration guidelines specify that Felina is for 'on-demand' or 'as needed' use, rather than a fixed daily schedule. The ingredients in the preparation are generally recognized as safe for topical use, and official instructions guide users to apply the product only when comfort or lubrication is required.

Q: Is it necessary to wash Felina off after use?

Official labeling for this type of water-based lubricant indicates that the product is water-soluble. While rinsing the product from the skin with water is possible, the product documentation does not include a formal requirement or instruction to wash the product off after every use.

Q: Does Felina stain clothes or sheets?

Felina is formulated as a water-based lubricant. Regulatory information for similar products indicates that they are typically water-soluble and non-staining. Any potential residue is generally expected to be removable with water, consistent with its water-based formulation.

Q: What should I do if I get Felina in my eyes?

Felina is strictly for external use, and contact with the eyes should be avoided. If the product makes contact with the eyes, it is generally advised to rinse the eyes thoroughly with clean water. If irritation persists after rinsing, consulting a healthcare provider is recommended.

How to Store and Dispose of Felina?

This section outlines the official, label-based requirements for storing, handling, and disposing of Felina to maintain product integrity and safety.

Requirement Category	Official Instructions
Storage Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze or expose to excessive heat.
Environmental Protection	Keep the product in its original, tightly closed container. Protect from both light and moisture.
Stability After Opening	If the product requires reconstitution, use the mixture within 14 days and store it under refrigeration. Discard any remaining portion after this period.
Child Safety	Keep Felina strictly out of the sight and reach of children at all times.
Disposal Instructions	Dispose of expired or unused Felina through a recognized drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance (e.g., dirt) and place it in a sealed bag before discarding it in the household trash. Do not flush the product.